These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9815947)
41. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754 [TBL] [Abstract][Full Text] [Related]
42. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. Boothe DM; Perkins J J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278 [TBL] [Abstract][Full Text] [Related]
43. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. Chan TC; Coppoc GL; Zimm S; Cleary S; Howell SB Cancer Res; 1988 Jan; 48(1):215-8. PubMed ID: 3334996 [TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483 [TBL] [Abstract][Full Text] [Related]
47. Acute dose-dependent disposition studies of nicotinic acid in rats. Iwaki M; Ogiso T; Hayashi H; Tanino T; Benet LZ Drug Metab Dispos; 1996 Jul; 24(7):773-9. PubMed ID: 8818575 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320 [TBL] [Abstract][Full Text] [Related]
49. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol. Muggia FM; Synold TW; Newman EM; Jeffers S; Leichman LP; Doroshow JH; Johnson K; Groshen S J Natl Cancer Inst; 1996 Oct; 88(20):1495-6. PubMed ID: 8841028 [No Abstract] [Full Text] [Related]
50. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Mendelsohn LG; Gates SB; Habeck LL; Shackelford KA; Worzalla J; Shih C; Grindey GB Adv Enzyme Regul; 1996; 36():365-81. PubMed ID: 8869756 [TBL] [Abstract][Full Text] [Related]
51. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Mendelsohn LG; Shih C; Schultz RM; Worzalla JF Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184 [TBL] [Abstract][Full Text] [Related]
52. Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography. Wedge SR; Laohavinij S; Taylor GA; Newell DR J Chromatogr B Biomed Appl; 1995 Jan; 663(2):327-35. PubMed ID: 7735480 [TBL] [Abstract][Full Text] [Related]
53. Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. Erlichman C; Soldin SJ; Hardy RW; Thiessen JJ; Sturgeon JF; Fine S; Baskerville T Arzneimittelforschung; 1988 Jun; 38(6):839-42. PubMed ID: 3178926 [TBL] [Abstract][Full Text] [Related]
55. Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. Synold TW; Xi B; Newman EM; Muggia FM; Doroshow JH J Chromatogr B Biomed Appl; 1996 Aug; 683(2):245-9. PubMed ID: 8891922 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Newman EM; Straw JA; Doroshow JH Cancer Res; 1989 Oct; 49(20):5755-60. PubMed ID: 2676149 [TBL] [Abstract][Full Text] [Related]
58. Disposition kinetics of dihydroquinidine following quinidine administration. Ueda CT; Williamson BJ; Dzindzio BS Res Commun Chem Pathol Pharmacol; 1976 Jun; 14(2):215-25. PubMed ID: 940955 [TBL] [Abstract][Full Text] [Related]
59. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs. Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]